The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
about
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young menCardiac cachexia: hic et nuncStudy Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)Nuclear receptors in bone physiology and diseasesAndrogen Receptor: A Complex Therapeutic Target for Breast CancerSkeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exerciseEpidemiology of sarcopenia and insight into possible therapeutic targets.Are we closer to having drugs to treat muscle wasting disease?Therapies for musculoskeletal disease: can we treat two birds with one stone?An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signalingEfforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention.Muscle wasting: an overview of recent developments in basic research.Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilizationAndrogen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndromeThe 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area.Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference.Emerging medication for the treatment of male hypogonadism.Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats.Enobosarm (GTx-024, S-22): a potential treatment for cachexia.Sex steroid actions in male boneMoving on up: the Journal of Cachexia, Sarcopenia and Muscle.Frailty and sarcopenia in elderly.Estrogens and Androgens in Skeletal Physiology and Pathophysiology.Development of selective androgen receptor modulators (SARMs).Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.Sarcopenia and Androgens: A Link between Pathology and Treatment.Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate-sparing anabolic therapy.Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!Molecular and cellular mechanisms of skeletal muscle atrophy: an update.Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs).Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.The role of muscle in bone repair: the cells, signals, and tissue responses to injuryEffects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trialCachexia vs obesity: where is the real unmet clinical need?Treatment of Hypogonadism: Current and Future Therapies.Difference in muscle quality over the adult life span and biological correlates in the Baltimore Longitudinal Study of Aging.
P2860
Q24561868-F53CC0EA-F50B-4CBB-B514-42B3A40CF88CQ26744140-34229D27-B429-4320-B49B-88B8AD6A1435Q26747940-D60DAEC2-BCCD-4463-B1FB-BE5C6E07FE40Q26853017-036A8D62-6503-4FED-B674-354B4DA991A7Q28075188-49158AC8-2FEF-4185-A29D-129F8E6CD973Q28262423-52B33CF0-F8A8-410D-8B00-702C7BAC3770Q30234579-2B1AB2AD-DA3E-47EF-8066-C7D78899BF40Q33741103-68862210-564E-44F4-9DAE-64A8FBB21EA1Q33851441-94B425D9-7F96-4F89-A766-A90FDE76CBD2Q33901722-A8AEC408-725F-484B-90A8-CE2018E21236Q33956866-3790B522-AF96-4FAF-8202-B9263895178CQ33966915-A8C4A862-BACE-4CDE-8E1E-597044AB4C39Q34156932-3F3EEA4E-4560-44F4-A2A6-013F2CDA0843Q34156942-1A296708-59C6-40EF-A48E-33BB4F79C614Q34203697-E8478F76-1F99-42F9-AE0F-1AC2EA3456E4Q34227893-E9BEA443-E067-4186-9675-A4D7943BF9BCQ34243652-32FC80F8-8FD4-4CF0-A018-C88ED05118A7Q34264508-94E30E93-3596-46A2-8E56-76E41D2713D6Q34276286-3A93A8BD-D8FA-48D4-8D12-2467140A9FCAQ34334313-7631CA32-9129-4E08-A9D0-8A870F67900AQ34398055-CA351E48-94F8-4738-AB35-B3BE68062F62Q34401825-C7E5AF56-81AE-4682-B3C5-72A507BA1094Q34437537-4660ED0F-D998-44D6-ABA4-C71364ED83BBQ34495485-F754895A-78F0-4158-8E13-AF8CA5F83BA5Q34541169-889A06E9-BD9B-4FC8-B1DE-59A5504D0D59Q34543980-29E8AF8D-DC4F-4215-A1FA-1A32D32EC6CBQ34558010-E2EA9B12-9451-4323-A674-3A63029BD8FAQ34591010-009D5845-4A85-4C75-94EC-D598DC81F8F4Q34730659-204784B1-BDF3-40A5-B824-ADC80226C2A4Q35093119-2FE7C634-BEDF-4E2E-AFD3-9FA8776ADEE1Q35223985-7A828863-FD8E-4265-8674-F325F7D124D5Q36179105-69DEC158-017B-4C78-B49B-C585E0BCFA15Q36473163-B7C074E5-E80E-4798-90A0-86A7DD89A4F5Q36706618-7213C0C3-34BE-45E9-95EE-48495366DD35Q36854062-BA9827AB-1337-4B1E-A4CE-7F4AD03AEE8DQ36974509-74099563-F616-4754-92E2-8D0B60287AC9Q36981247-B68D05E4-FCA6-4C16-A4F4-9A08BAAACF1DQ37313726-291BDAF9-9BC9-4555-AFEC-6160876438CCQ37605378-7795F5D4-5ADD-4C77-B89B-A4561087EC55Q37622719-B1179930-426F-4F5C-BC04-4DCBC992D0C5
P2860
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The selective androgen recepto ...... ebo-controlled phase II trial.
@ast
The selective androgen recepto ...... ebo-controlled phase II trial.
@en
The selective androgen recepto ...... ebo-controlled phase II trial.
@nl
type
label
The selective androgen recepto ...... ebo-controlled phase II trial.
@ast
The selective androgen recepto ...... ebo-controlled phase II trial.
@en
The selective androgen recepto ...... ebo-controlled phase II trial.
@nl
prefLabel
The selective androgen recepto ...... ebo-controlled phase II trial.
@ast
The selective androgen recepto ...... ebo-controlled phase II trial.
@en
The selective androgen recepto ...... ebo-controlled phase II trial.
@nl
P2093
P2860
P1476
The selective androgen recepto ...... cebo-controlled phase II trial
@en
P2093
Casey E Bohl
Domingo Rodriguez
Kester G Barnette
Michael L Hancock
Mitchell S Steiner
Ronald A Morton
Shontelle T Dodson
P2860
P2888
P304
P356
10.1007/S13539-011-0034-6
P577
2011-08-02T00:00:00Z
P5875
P6179
1025519068